Rezolute Inc is trading at $4.43 (+10.75%) after the company reported positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism.
- The update revealed the study has reached 50% enrollment, with a significant majority of participants already meeting the primary endpoint.
- Today's price action extends positive momentum from June 2, when the stock saw a 10.80% gain.